Cynata’s (ASX: CYP) data on consistency of Cymerus™ MSCs released at leading Stem Cell Research Conference

November 16, 2022 06:04 PM AEDT | By Aditi Sarkar

Cynata’s (ASX: CYP) data on consistency of Cymerus™ MSCs released at leading Stem Cell Research Conference — Image source: © Yur4you | Megapixl.com

Recent News

Judo Bank Shares Slide on Growth Revision Amid ASX 200 Volatility

Resolution Minerals Taps High-Grade Potential with Strategic Acquisiti...

How Did Burgundy Diamond Mines Perform in the First Quarter of 2025?

Tesla Leadership Speculation Quashed Amid Strong Confidence in Musk –...

Highlights

Data demonstrating the consistency of Cynata’s Cymerus™ MSCs has been presented at a leading Stem Cell Research Conference held in Melbourne.

The study further validates the potential of Cymerus MSCs as an off-the-shelf cell therapy.

The major findings of the study include:

Cymerus™ MSCs exhibit less batch-to-batch heterogeneity (variability) than tissue-derived MSCs.

Cymerus™ MSCs also exhibit significantly less variability within each batch.

Cynata Therapeutics (ASX:CYP), a clinical-stage cell therapeutics company, announced the conference presentation of data from a study on the consistency of Cymerus™ mesenchymal stem cells (MSCs) and MSCs derived from various tissue sources. Manufacturing consistency is an absolute requirement in the manufacture of pharmaceutical products, so these findings confirm an important competitive advantage of Cymerus MSCs compared with MSCs derived from donor tissues.

The study endorses the potential of Cymerus MSCs as an off-the-shelf cell therapy. It also offers a better insight into the sources of MSC variability to have more predictable clinical outcomes.

The data was presented at the Biennial Australasian Society for Stem Cell Research (ASSCR) and Australasian Gene and Cell Therapy Society (AGCTS) Scientific Meeting in Melbourne.

Below are the major findings of the study

The study, carried out at Monash University by a team of scientists led by Associate Professor Jess Frith, compared the consistency of different batches of MSCs. It included Cymerus™ induced pluripotent stem cell (iPSC)-derived MSCs and tissue-derived MSCs from adipose tissue, bone marrow and umbilical cord.

The next-generation single-cell sequencing technique was used to profile the gene expression of the different MSCs at the individual cell level.

At the time of writing this article, share price of Cynata was AU$0.305 apiece.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.